Does lowering cholesterol cause cancer?

Deciding who should be screened and treated for elevated cholesterol levels has profound implications for the health of our nation. Depending on the selection criterion for screening, the costs of screening and treatment and the potential savings by preventing myocardial infarction and death from coronary heart disease (CHD) can be staggering. The two extreme positions regarding the appropriate population to be screened and treated are those of the National Cholesterol Education Program (NCEP) 1 and of Hulley and his associates. 2 The NCEP recommends that all Americans aged 20 years and older be screened for high cholesterol and has prepared dietary and drug therapy guidelines for patients, millions of whom do not have clinical evidence of CHD. Since CHD is a progressive disease that may take decades to become manifest, the NCEP recommends primary as well as secondary prevention. See also p 55. Hulley and coworkers have reported that screening

[1]  S. Hulley,et al.  Carcinogenicity of lipid-lowering drugs. , 1996, JAMA.

[2]  W C Willett,et al.  The causes and prevention of cancer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Hulley,et al.  Cholesterol in the elderly. Is it important? , 1994, JAMA.

[4]  J. Dalen,et al.  Cholesterol and violent behavior. , 1994, Archives of internal medicine.

[5]  M. Law,et al.  Assessing possible hazards of reducing serum cholesterol , 1994, BMJ.

[6]  J. Huttunen,et al.  The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐up , 1994, Journal of internal medicine.

[7]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[8]  B. Ames,et al.  Rodent carcinogens: setting priorities. , 1992, Science.

[9]  S. Hulley,et al.  Health policy on blood cholesterol. Time to change directions. , 1992, Circulation.

[10]  G. Davey Smith,et al.  Should there be a moratorium on the use of cholesterol lowering drugs? , 1992, BMJ.

[11]  W. Browner,et al.  The case against childhood cholesterol screening. , 1990, JAMA.

[12]  B. Ames,et al.  Chemical carcinogenesis: too many rodent carcinogens. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Herbert S. Rosenkranz,et al.  Information value of the rodent bioassay , 1988, Nature.

[14]  L. Gold,et al.  Ranking possible carcinogenic hazards. , 1987, Science.

[15]  J. Cutler,et al.  Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. , 1987, JAMA.

[16]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[17]  J. Mordenti,et al.  Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.

[18]  B. Ames,et al.  Chronological supplement to the Carcinogenic Potency Database: standardized results of animal bioassays published through December 1982. , 1986, Environmental health perspectives.

[19]  M. Pike,et al.  A carcinogenic potency database of the standardized results of animal bioassays , 1984, Environmental health perspectives.

[20]  L. Kuller.  Sudden death--definition and epidemiologic considerations. , 1980, Progress in cardiovascular diseases.

[21]  M. L. Pearce,et al.  Incidence of cancer in men on a diet high in polyunsaturated fat. , 1971, Lancet.

[22]  S. Kritchevsky,et al.  Serum cholesterol and cancer risk: an epidemiologic perspective. , 1992, Annual review of nutrition.

[23]  H. Bartsch,et al.  The contribution of experimental studies to risk assessment of carcinogenic agents in humans. , 1990, Experimental pathology.

[24]  Jeremy N. Morris,et al.  W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. , 1980 .